Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers (Q73290319)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

D B Sodee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

N Malguria

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P Faulhaber

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M I Resnick

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

G Bakale

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 December 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

988-993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Prostate-specific membrane antigen (PSMA): current benefits and future value

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Prostate-specific membrane antigen: present and future applications

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Staging errors in clinically localized prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

The effectiveness of imaging modalities in clinical staging of localized prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

PSA decline is an independent prognostic marker in hormonally treated prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Two different lymph node metastatic patterns of a prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

Considerations regarding prostate biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900824-4

7 January 2021

10.1016/S0090-4295(00)00824-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113745%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference